Lundbeck persuades NICE to back Brintellix; Drugmakers win fight over 340B orphan drug discounts;

@FiercePharma: ICYMI: Boehringer looks for Pradaxa boost from now FDA-approved antidote. Article | Follow @FiercePharma

@EricPFierce: Pests, lack of data integrity thwart another Indian API maker, this time Unimark Remedies. More | Follow @EricPFierce

@CarlyHFierce: Shire's eye drug setback gives Allergan's Restasis a temporary reprieve. Story | Follow @CarlyHFierce

> Danish drugmaker Lundbeck used additional data to persuade cost-effectiveness watchdogs in England to back its new antidepressant Brintellix. Report

> Drugmakers prevailed in their latest fight against 340B hospital discounts on orphan drugs in nonorphan indications. Report

> Sprout Pharmaceuticals rolled out the controversial female libido drug Addyi on Saturday, and analysts are saying that safety issues with the med could spur development of better follow-up drugs. Report

> Sanofi ($SNY) and Regeneron ($REGN) rolled out their cholesterol-fighting PCSK9 drug Praluent in the U.K., going up against Amgen's ($AMGN) Repatha, which launched there last month. Report

> Allergan ($ACT) wrapped up its buyout of the eye care company AqueSys and its experimental glaucoma-focused device. Report

Medical Device News

@FierceMedDev: Check out this year's Fierce 15: The new strategic med tech mania sets the stage for 2015's Fierce 15. Feature | Follow @FierceMedDev

@VarunSaxena2: #TCT15: Startup's minimally invasive mitral valve repair tech shows promise in feasibility study. Story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI: European investor shells out $118M for DNA testing outfit to boost animal Dx offerings. Article | Follow @EmilyWFierce

> Sientra slides amid implant manufacturing fallout in Brazil. Article

> FDA commissioner nominee stresses need to improve combination product reviews. Story

Biotech News

@FierceBiotech: ICYMI Friday: Biotech notches another $2B VC quarter, but can it last? Story | Follow @FierceBiotech

@JohnCFierce: Shire hit with another setback as FDA rejects top pipeline drug- Does anyone think that Ornskov is a good CEO? Article | Follow @JohnCFierce

@DamianFierce: Not often a company issues two separate statements on a single drug rejection. Not often a company issues two separate statements on a single drug rejection. More | Follow @DamianFierce

> Genocea halts its antibiotic vaccine program after a Phase II failure. Story

> Basilea plots $190M IPO on Nasdaq as it circles a PhIII antibiotic study. Article

Animal Health News

> European investor shells out $118M for DNA testing outfit to boost animal Dx offerings. Story

> Dog study validates Blaze 'tumor paint' for guiding surgery. Report

> Nexvet launches field trial of treatment for feline osteoarthritis. More

> Ceva, Harrisvaccines nab USDA contracts for bird flu vaccines. Article

> Dogs with cleft palates add to knowledge of condition in children. Story

Biotech IT News

> Venter's Human Longevity starts $50,000 health testing service. News

> LabKey lands data-management deal with 100,000 Genomes Project. More

> EU consortium creates large toxin database for drug discovery. Report

> Scripps teams up to apply genomics to stem cell quality control. Story

> 23andMe raises $115M as investors buy into data-driven drug discovery vision. Article

Pharma Marketing News

> One year after FDA nod, Eli Lilly's Trulicity launches first consumer campaign. Item

> Merck KGaA exits 'sea of sameness' with futuristic rebrand. Editor's corner

> Pacira sues for free speech; FDA pulls off-label warning letter. What gives? More

> Bayer consumer biz on digital agency hunt, in shift from 'TV-centric' to 'channel-agnostic.' Article

> Influential cancer group releases first batch of affordability info on cancer meds. Item

And Finally... The Novartis ($NVS) cancer drug Tasigna delivered "meaningful clinical improvements" in 10 of 11 Parkinson's disease patients in an early-stage trial. Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.